A Phase 1/2a Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493, a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects With Advanced Hepatocellular Carcinoma
Phase of Trial: Phase I
Latest Information Update: 07 Jan 2018
At a glance
- Drugs Erdafitinib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Janssen Research & Development
- 17 Oct 2017 Planned End Date changed from 31 May 2019 to 28 Feb 2019.
- 17 Oct 2017 Planned primary completion date changed from 31 May 2019 to 28 Feb 2019.
- 17 Aug 2017 Planned number of patients changed from 58 to 55.